You are here: Industry Insights > Roche

News List

Japan becomes the first country to approve Roche's personalised medicine Rozlytrek worldpharmanews
June 20, 2019
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek.
Japan the first to approve Roche’s personalised medicine Rozlytrek biospectrumasia
June 19, 2019
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours
Japan First to Approve Roche’s Rozlytrek contractpharma
June 19, 2019
A tumor-agnostic medicine for treatment of adult and pediatric patients with NTRK fusion-positive advanced recurrent solid tumors/
FDA Approves Roche's Kadcyla for HER2-Positive Early Breast Cancer contractpharma
June 14, 2019
An adjuvant treatment for patients who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
Regulators demand more details on Roche’s $4.8bn Spark acquisition pharmaceutical-technology
June 13, 2019
The US Federal Trade Commission (FTC) has requested that both Roche and Spark Therapeutics submit additional information and documentary material regarding their proposed merger agreement.
FDA Approves Roche’s Venclexta for CLL contractpharma
June 12, 2019
Venclexta combined with Gazyva is an approved chemotherapy-free option for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).
Roche launches first in vitro lung cancer diagnostic test pharmatimes
June 11, 2019
Roche Diagnostics has launched its first in vitro diagnostic test to target ROS1 positive lung cancers, VENTANA ROS1 (SP384) Antibody.
AbbVie, Roche present positive Venclyxto results at ASCO pharmatimes
June 05, 2019
AbbVie and Roche have announced data from the CLL14 trial, evaluating Venclyxto (venetoclax) plus Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia.
Roche receives FDA approval for Venclexta plus Gazyva in CLL pharmaceutical-technology
May 22, 2019
Roche has obtained approval by the US Food and Drug Administration (FDA) for Venclexta (venetoclax) and Gazyva (obinutuzumab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents worldpharmanews
May 21, 2019
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page